This article was originally published in Start Up
Anti-angiogenesis as a treatment for cancer was hardly a new concept, even in 1998 when a New York Times article first put Judah Folkman's work on the public map. Although the hype has died away, the industrial machine of anti-angiogenesis has continued to roll on--as indicated by the start-up activity we describe in the following profiles.
You may also be interested in...
With two product candidates in its portfolio--contortrostatin (an anti-angiogenic agent purified from snake venom), and a proprietary low-dose version of interleukin-2--Pivotal BioSciences hopes to be a catalyst for other university-based researchers in the Los Angeles area to develop their discoveries under its corporate umbrella.
Founded in close affiliation with Denver's AMC Cancer Research Center, Oncology Sciences Corp. is taking a natural approach to fighting prostate cancer. It is focusing on preclinical development of an endogenous angiogenesis inhibitor as well as other natural substances that work through anti-angiogenic and additional mechanisms.
The enthusiasm of the founders of Cell Matrix, which was founded in late 1999 to pursue its own anti-angiogenesis approach to cancer, hasn't been dampened by the failures of its forebears. They believe the company has what competitors lack: a family of antibodies that is selective for angiogenesis.